BCYC logo

Bicycle Therapeutics plc

BCYC
Healthcare|Biotechnology|GB
$3.61
+0.13 (+3.74%)
Tangible Book / Share
$7.22
Cash / Share
$6.72
Next Earnings Report
Mar 2, 2027
EPS est. -$0.44 · Revenue est. $2.5M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (6)

Dec 2026
Est. completion
P1P2Advanced Solid Tumor Historically Known for High EphA2 Expression
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371n=288
Jan 2027
Est. completion
P1P2Urinary Bladder Neoplasm
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
NCT04561362n=329
Mar 2028
Est. completion
P2Metastatic Urothelial Cancer
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596n=375
Jun 2028
Est. completion
P2Breast Cancer
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT06840483n=66
Aug 2028
Est. completion
P2Non-Small Cell Lung Cancer
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
NCT06933329n=73
Mar 2029
Est. completion
P2Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07450859n=39

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Aug 2026
P1P2
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
NCT05163041

Recent Press Releases

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Oct 29, 2026 · Business Wire

SEC Filings (65)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 29, 202610-QQuarterly reportDocumentIndex
Oct 29, 20268-KMaterial eventDocumentIndex
Aug 20, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 30, 202610-QQuarterly reportDocumentIndex
Jul 30, 20268-KMaterial eventDocumentIndex
Jun 18, 20268-KMaterial eventDocumentIndex
May 21, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 4, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Apr 30, 202610-QQuarterly reportDocumentIndex
Apr 30, 20268-KMaterial eventDocumentIndex
Apr 22, 2026ARSAnnual report to holdersDocumentIndex
Apr 22, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 20, 20268-KMaterial eventDocumentIndex
Apr 3, 2026PRE 14AProxy / shareholder voteDocumentIndex
Mar 17, 2026S-8Employee stock planDocumentIndex
Mar 17, 202610-KAnnual reportDocumentIndex
Mar 17, 20268-KMaterial eventDocumentIndex
Mar 4, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 3, 2026SC 13GPassive 5%+ stakeDocumentIndex
Mar 3, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 3, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 18, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 11, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 3, 20268-KMaterial eventDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Oct 30, 2025S-8Employee stock planDocumentIndex
Oct 30, 202510-QQuarterly reportDocumentIndex
Oct 30, 20258-KMaterial eventDocumentIndex
Sep 8, 20258-KMaterial eventDocumentIndex
Aug 14, 2025EFFECTDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2025424B3Offering prospectusDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 8, 2025S-3Shelf registrationDocumentIndex
Aug 8, 202510-QQuarterly reportDocumentIndex
Aug 8, 20258-KMaterial eventDocumentIndex